Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
Provided By GlobeNewswire
Last update: May 28, 2025
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone--
Read more at globenewswire.com2.6
-0.35 (-11.86%)
Find more stocks in the Stock Screener
VERU Latest News and Analysis
